GNCA - ジェノシア・バイオサイエンシズ （Genocea Biosciences Inc.） ジェノシア・バイオサイエンシズGNCAのチャート
GNCAの企業情報
| symbol | GNCA |
|---|---|
| 会社名 | Genocea Biosciences Inc （ジェノシア・バイオサイエンシズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 ジェノセア・バイオサイエンス(Genocea Biosciences Inc.)はT細胞免疫力を利用してワクチンと免疫療法を開発する。同社はその発見プラットフォームであるAnTigen Lead Acquisition System（ATLAS）を使用して、一部はT細胞（または細胞）免疫反応によって作用するワクチンおよび免疫療法を設計する。同社は、第III相臨床開発における1つの製品候補であり、性器ヘルペスの治療のための免疫療法であるGEN-003を有する。また、パーソナライズされた癌ワクチン（GEN-009）に焦点を合わせた前臨床免疫腫瘍学プログラムを有する。そのGEN-009プログラムは、ATLASを利用して、個体の腫瘍に関連する患者新生抗原、または各患者に固有の新たに形成された抗原を同定する。 ジェノシア・バイオサイエンシズは、米国のバイオ医薬品企業。ATLASプラットフォ―ム技術を用いて新型ワクチンの開発に従事。単純ヘルペスウイルス2型(HSV-2)の治療薬や、肺炎球菌の感染予防用ワクチンの製品候補の開発を手掛ける。またクラミジア予防プログラム、HSV-2予防プログラム、マラリア予防プログラムなど開発プログラムを手掛ける。 Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood. |
| 本社所在地 | 100 Acorn Park Drive Cambridge MA 02140 USA |
| 代表者氏名 | Katrine S. Bosley Katrine S. Bosley |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 617-876-8191 |
| 設立年月日 | 38930 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2014年 |
| 従業員数 | 52人 |
| url | www.genocea.com |
| nasdaq_url | https://www.nasdaq.com/symbol/gnca |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -43.25400 |
| 終値（lastsale） | 0.8 |
| 時価総額（marketcap） | 69300780 |
| 時価総額 | 時価総額（百万ドル） 62.71721 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 33.67221 |
| 当期純利益 | 当期純利益（百万ドル） -47.92800 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Genocea Biosciences Inc revenues was not reported. Net loss decreased 30% to $20.3M. Lower net loss reflects Research and Development - Bal Val decrease of 40% to $12.3M (expense) General and administrative decrease of 35% to $936K (expense) stock based-Research and development decrease of 59% to $300K (expense). |
GNCAのテクニカル分析
GNCAのニュース
Thinking about buying stock in Mullen Automotive, Endo International, AMC Entertainment, Tellurian, or Genocea Biosciences? 2022/06/01 15:00:00 Benzinga
NEW YORK , June 1, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MULN, ENDP, AMC, TELL, and GNCA. … Full story available on Benzinga.com
Genocea Biosciences Inc. (NASDAQ: GNCA): Sinking Weak -97.32% In 2022, Outlook Strong 2022/06/01 11:00:00 Stocks Register
The trading price of Genocea Biosciences Inc. (NASDAQ:GNCA) closed lower on Tuesday, May 31, closing at $0.06, -1.94% lower than its previous close. >> 5 Best Growth Stocks for 2022 << >> 5 Best Growth Stocks for 2022 << Traders who pay close attention to intraday price movement should know that it fluctuated between $0.05 … Genocea Biosciences Inc. (NASDAQ: GNCA): Sinking Weak -97.32% In 2022, Outlook Strong Read More »
The Week Ahead In Biotech (May 30-June 4): FDA Decision For Eton''s Partnered Epilepsy Drug, ASCO Conference Gets Underway And More 2022/05/30 18:03:17 Benzinga
Biotech stocks advanced in the week ended May 27, tracking the overall positive sentiment of the broader market. Notwithstanding the week''s strength, the sector has been one of the worst performers for the year-to-date period. Among notable developments, Genocea Biosciences, Inc. (NASDAQ: GNCA ) announced that it is shuttering operations amid a cash crunch. The company also plans to voluntarily delist its shares from Nasdaq by June 2. Verrica Pharmaceuticals, Inc. (NASDAQ: VRCA ) suffered a setback after its viral skin infection treatment candidate was rejected by the Food and Drug Administration on its third try. Catalyst Biosciences, Inc. (NASDAQ: CBIO ) shares skyrocketed after the company announced a deal to sell its portfolio of protease medicines that regulate complement to Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX ). Looking ahead, the American Society of Clinical Oncology, or ASCO, the meeting is likely to be in the spotlight this week. Presentations at the conference have the …
GRPN, GNCA and LAB among mid-day movers 2022/05/25 16:49:22 Seeking Alpha
Gainers: BlackSky Technology BKSY +93%.StoneMor STON +51%.Genocea Biosciences (GNCA) +35%.Hoegh LNG Partners HMLP +31%.Caleres CAL +27%.Evelo Biosciences EVLO +20%.Spire Global…
Genocea stock slips on cutting workforce by 65% and exploring sale or merger alternatives 2022/04/29 09:46:53 Seeking Alpha
Genocea Biosciences (GNCA) has initiated a process to explore a range of strategic alternatives to maximize shareholder value, including the sale of all or part of the company, merger…
Swinging stocks: Genocea Biosciences, Inc. (NASDAQ:GNCA -5.45%), Indonesia Energy Corporation Limited (AMEX:INDO 65.93%) 2022/04/18 13:59:18 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Swinging stocks: Genocea Biosciences, Inc. (NASDAQ:GNCA -5.45%), Indonesia Energy Corporation Limited (AMEX:INDO 65.93%) appeared first on Stocks Equity .
Eye-catching Hot Stock: Occidental Petroleum Corporation (NYSE:OXY), Genocea Biosciences, Inc. (NASDAQ:GNCA) 2022/04/14 12:40:24 Stock Equity
Occidental Petroleum Corporation (OXY) with the stream of 0.81% also noticed, India Genocea Biosciences, Inc. (GNCA) encountered a rapid change of -0.71% in the last hour of Wednesday’s trading session. … The post Eye-catching Hot Stock: Occidental Petroleum Corporation (NYSE:OXY), Genocea Biosciences, Inc. (NASDAQ:GNCA) appeared first on Stocks Equity .
Genocea Biosciences Stock Dives After Early Data From GEN-011 Trial In Pretreated Solid Tumor Patients 2022/04/08 18:32:10 Benzinga
Genocea Biosciences Inc (NASDAQ: GNCA ) has shared initial data from Phase 1/2a TiTAN trial OF GEN-011 in patients with refractory solid tumors. The company says that the early results presented at American Association for Cancer Research (AACR) show anti-tumor activity despite the lower intensity regimens and heavily pretreated tumors. Stable disease was seen at the initial … Full story available on Benzinga.com
Volkswagen recalls 246,000 Atlas SUVs due to issue with airbags, brakes 2022/03/20 05:57:03 Kwhen Finance
Genocea to Present at the 11th Annual SVB Leerink Global Healthcare Conference 2022/02/11 00:50:00 GlobeNewswire
CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, President and Chief Executive Officer, will present a corporate overview at the virtual 11 th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17 th at 10:40 A.M. ET.
Genocea to Present at Upcoming Investor Conferences 2022/01/05 22:46:00 GlobeNewswire
CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior leadership plans to present at the following conferences in January.
Genocea Biosciences Inc Shares Close the Day 19.7% Higher - Daily Wrap 2021/12/25 15:25:34 Kwhen Finance
Genocea Biosciences Inc (GNCA) shares closed today 19.7% higher than it did at the end of yesterday. The stock is currently down 48.6% year-to-date, down 51.7% over the past 12 months, and down 96.7% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $1.35 and as low as $0.91 this week.Shares closed 69.3% below its 52-week high and 36.8% above its 52-week low.Trading volume this week was 84.2% lower than the 10-day average and 56.9% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -351.5% The company's stock price performance over the past 12 months lags the peer average by -520.0%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
Genocea Biosciences Inc Shares Close the Day 19.7% Higher - Daily Wrap 2021/12/24 05:27:03 Kwhen Finance
Genocea Biosciences Inc (GNCA) shares closed today 19.7% higher than it did at the end of yesterday. The stock is currently down 57.0% year-to-date, down 58.9% over the past 12 months, and down 97.0% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $1.35 and as low as $0.91 this week.Shares closed 69.3% below its 52-week high and 36.8% above its 52-week low.Trading volume this week was 55.2% higher than the 10-day average and 69.0% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.8. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -379.0% The company's stock price performance over the past 12 months lags the peer average by -454.3%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
Thinking about buying stock in Ensysce Biosciences, Turkcell Iletisim Hizmetleri A.S., Genocea Biosciences, Inspira Technologies, or Biofrontera? 2021/12/23 13:31:00 PR Newswire
NEW YORK, Dec. 23, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ENSC, TKC, GNCA, IINN, and BFRI. To see how InvestorsObserver''s proprietary scoring system rates these stocks, view the InvestorsObserver''s PriceWatch Alert by selecting the corresponding link.